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First line chemotherapy is effective in 75 to 80% of patients with metastatic colorectal cancer
(mCRC). We studied whether microRNA (miR) expression profiles can predict treatment
outcome for first line fluoropyrimidine containing systemic therapy in patients with mCRC.
Methods
MiR expression levels were determined by next generation sequencing from snap frozen
tumor samples of 88 patients with mCRC. Predictive miRs were selected with penalized
logistic regression and posterior forward selection. The prediction co-efficients of the miRs
were re-estimated and validated by real-time quantitative PCR in an independent cohort of
81 patients with mCRC.
Results
Expression levels of miR-17-5p, miR-20a-5p, miR-30a-5p, miR-92a-3p, miR-92b-3p and
miR-98-5p in combination with age, tumor differentiation, adjuvant therapy and type of sys-
temic treatment, were predictive for clinical benefit in the training cohort with an AUC of
0.78. In the validation cohort the addition of the six miR signature to the four clinicopathologi-
cal factors demonstrated a significant increased AUC for predicting treatment response ver-
sus those with stable disease (SD) from 0.79 to 0.90. The increase for predicting treatment







Citation: Neerincx M, Poel D, Sie DLS, van Grieken
NCT, Shankaraiah RC, van der Wolf - de Lijster
FSW, et al. (2018) Combination of a six microRNA
expression profile with four clinicopathological
factors for response prediction of systemic
treatment in patients with advanced colorectal
cancer. PLoS ONE 13(8): e0201809. https://doi.
org/10.1371/journal.pone.0201809
Editor: Alfons Navarro, Universitat de Barcelona,
SPAIN
Received: January 5, 2018
Accepted: July 22, 2018
Published: August 3, 2018
Copyright: © 2018 Neerincx et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Genome data has
been deposited at the European Genome-phenome
Archive EGA, http://www.ebi.ac.uk/ega/, which is
hosted at the European Bioinformatics Institute
(EBI), under accession number
EGAS00001001127.
Funding: This work was supported by an
unrestricted donation from Aegon N.V. The
Netherlands.
response versus progressive disease (PD) and for patients with SD versus those with PD
was not significant. in the validation cohort. MiR-17-5p, miR-20a-5p and miR-92a-3p were
significantly upregulated in patients with treatment response in both the training and valida-
tion cohorts.
Conclusion
A six miR expression signature was identified that predicted treatment response to fluoro-
pyrimidine containing first line systemic treatment in patients with mCRC when combined
with four clinicopathological factors. Independent validation demonstrated added predictive
value of this miR-signature for predicting treatment response versus SD. However, added
predicted value for separating patients with PD could not be validated. The clinical relevance
of the identified miRs for predicting treatment response has to be further explored.
Introduction
Colorectal cancer (CRC) is the third most common cancer worldwide and has a 5 year survival
of only 13% when disseminated [1, 2]. Approximately 20% of patients present with metastatic
disease (mCRC) and another 25–30% will develop metastases after initial surgical resection of
their primary tumor [3]. For patients with resectable metastases several localized treatment
options are available [4]. Patients with initially irresectable metastases are treated with systemic
therapy consisting of a fluoropyrimidine (5-fluorouracil or capecitabine), oxaliplatin and/or
irinotecan and a biological agent (bevacizumab, cetuximab or panitumumab) in a neoadjuvant
or palliative setting. First line systemic therapy induces a treatment response or disease stabili-
zation in 75–80% of patients with mCRC [5–8]. Consequently, 20–25% of patients receive sys-
temic treatment without any benefit while causing multiple toxicities.
Predictive biomarkers for treatment benefit prior to the start of treatment can prevent the
use of ineffective treatment regimens, avoid unnecessary toxicity and minimize the delay of
treatment with alternative effective regimens. At this moment RAS mutation status is the only
routine biomarker to predict treatment benefit in patients with mCRC [9, 10]. Small non-cod-
ing microRNAs (miRs) are an attractive source for predictive biomarker development as they
post-transcriptionally regulate many target genes involved in carcinogenesis. MiRs are deregu-
lated in the tumor genome. They are frequently located at genomic regions with gains or losses
in the tumor genome and abnormalities in miR processing genes or proteins can enhance can-
cer development [11, 12]. As miRs are relatively resistant to degradation in formalin fixed and
paraffin embedded (FFPE) material as well as in blood, they are suited for the use as biomark-
ers in clinical practice [13–15]. Indeed, miR expression levels distinguishes different tumor
types from normal tissue and have been identified as potential biomarkers for mCRC [16, 17].
Currently, miRs with prognostic and predictive value have been identified for localized and
metastasized CRC [18–25]. However, these miRs were identified by probe based methodolo-
gies and consequently these studies were inherently restricted to a limited number of miRs.
We previously identified 222 tumor specific miRs differentially expressed between CRC tumor
tissue and corresponding normal tissue by an unbiased whole genome approach using next
generation sequencing (NGS) [17]. Here, we used NGS to identify a predictive miR expression
profile based on these tumor specific miRs for patients with mCRC treated with first line
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fluoropyrimidine-based treatment regimens and examined its performance in an independent
patient group.
Materials and methods
Patients and tumor samples
A total of 169 patients with mCRC were included. Patients with known Lynch syndrome or
CRC secondary to inflammatory bowel disease or patients who were treated with neoadjuvant
radiotherapy or with chemotherapy within 6 months before tumor resection were excluded for
this study. Samples were collected from consecutive patients who entered the VU University
Medical Center from July 2003 until November 2011 or the Spaarne Hospital from January
2005 until December 2010. Retrospective collection, storage and use of patient data were
approved by the Medical Ethical Committee of the VU University Medical Center. Written or
verbal informed consent was not obtained due to the retrospective nature of the study in con-
cordance with Dutch law. All patients were deceased or lost to follow-up. Collection, storage
and use of tumor samples were performed in accordance with the Code for proper secondary
use of human tissue in The Netherlands [26].
Samples of primary as well as metastatic tumor tissue were included as miR profiles from
metastatic tumor tissue only differ by 0,5% from their corresponding primary tumor [17].
Patients were synchronously metastasized in 62.7% (stage IV at presentation) and metachro-
nously metastasized in 36.7% (stage I-III at presentation) of the cases (Table 1). Patients were
treated with first line systemic treatment for mCRC for at least 6 weeks. Treatment consisted
of a fluoropyrimidine (infusional 5-fluorouracil or oral capecitabine), oxaliplatin, irinotecan
or combinations. Additional anti-VEGF (bevacizumab) or anti-EGFR monoclonal antibodies
(cetuximab or panitumumab) were allowed. Computed tomography or ultrasound imaging
was performed before and during treatment to evaluate response rates in all 169 patients. Sam-
ples were divided into a training and validation cohort based on the availability of fresh-frozen
tumor samples.
Fresh frozen tumor samples were available for 103 patients. In 15 samples tumor cell content
was less than 70% and therefore these were excluded prior to the analysis to enhance the selec-
tion of tumor specific miRs during classifier development. The 88 training samples included 80
primary tumors, 5 metastases and 3 local recurrences and were directly frozen after surgery.
FFPE tumor samples were available for 88 patients. Seven samples were not evaluable due
to low RNA quantity or inability to amplify the RNA with RT-qPCR and were excluded prior
to the analysis. The 81 validation samples included 54 primary tumor resection specimens, 26
primary tumor biopsies obtained before start of systemic treatment and 1 metastasis. No mini-
mal tumor cell percentage was required for inclusion in the validation cohort, but all contained
>40% tumor cells.
Clinical and pathological factors
Clinical and pathological data with known predictive or prognostic value were collected. Data
on the use of local treatment modalities for metastatic disease after start of systemic treatment
and the total number of different systemic treatment regimens were collected as well. Potential
predictive factors for tumor response included; age at start of systemic treatment for advanced
disease (continuous variable), primary tumor differentiation (well or moderate versus poor
or with signet cell differentiation), previous adjuvant treatment (either for localized CRC or
after local treatment for metastases) (yes versus no) and treatment regimen (fluoropyrimidine
mono-therapy versus oxaliplatin containing regimens versus irinotecan containing regimens).
Primary tumor differentiation grade was missing for 12 tumor samples in the validation
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cohort because the primary tumor was not resected and the pretreatment biopsies did not
yield enough material to reliably determine the differentiation grade.
Additional potential prognostic factors for progression free survival (PFS) included initial
tumor stage (synchronous versus metachronous disease, with synchronous and metachronous
Table 1. Baseline characteristics of the 169 patients with advanced colorectal cancer included in the training and validation cohorts.
Training cohort (N = 88) Validation cohort (N = 81) P value1
Sex—N (%) 1.00
Female 32 (36.4) 30 (37.0)
Male 56 (63.6) 51 (63.0)
Age—yr 0.01
Median (range) 65 (41–88) 61 (37–81)
Primary tumor location—N (%) 0.005
Rectal 9 (10.2) 20 (24.7)
Left sided 53 (60.2) 30 (37.0)
Right sided 26 (29.5) 31 (38.3)
TNM-stage at time of diagnosis2 - N (%) 0.21
Stage I 3 (3.4) 1 (1.2)
Stage II 10 (11.4) 13 (16.0)
Stage III 23 (26.1) 12 (14.8)
Stage IV 52 (59.1) 54 (66.7)
Missing data 0 1 (1.2)
Primary tumor differentiation3 - N (%) 0.99
Well 1 (1.1) 1 (1.2)
Moderate 68 (77.3) 53 (65.4)
Poor 19 (21.6) 15 (18.5)
Missing data 0 12 (14.8)
Prior adjuvant therapy for localized CRC—N (%) 0.001
No 68 (77.3) 77 (95.1)
Yes 20 (22.7) 4 (4.9)
Prior adjuvant therapy for advanced CRC4 - N (%) 1.00
No 85 (96.6) 78 (96.3)
Yes 3 (3.4) 3 (3.7)
Liver metastases only—N (%) 0.04
No 48 (54.5) 57 (70.4)
Yes 40 (45.5) 24 (29.6)
LDH—N (%) 0.86
Normal (<250 ng/ul) 20 (22.7) 23 (28.4)
Elevated (250 ng/ul) 52 (59.1) 55 (67.9)
Missing data 16 (18.2) 3 (3.7)
CEA—N (%) 1.00
Normal (<5 ng/ul) 16 (18.2) 17 (21.0)
Elevated (5ng/ul) 61 (69.3) 61 (75.3)
Missing data 11 (12.5) 3 (3.7)
1 P values were calculated with Fisher’s exact test, except for age which was calculated with the unpaired t-test, and primary tumor location, TNM stage and primary
tumor differentiation which were calculated with the chi-square test
2 Stage IV was defined as metastatic disease diagnosed within 30 days of resection of the primary tumor.
3 Signet cell differentiation was classified as poorly differentiated
4 Macroscopic disease free after local treatment for metastatic disease, preceding first line treatment
Abbreviations: LDH, lactate dehydrogenase, CEA, carcinoembryonic antigen
https://doi.org/10.1371/journal.pone.0201809.t001
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disease defined as distant metastases occurring respectively within and beyond 30 days of pri-
mary diagnosis of CRC), metastatic tumor load (liver metastases only versus involvement of
other organs), lactate dehydrogenase (LDH) (normal versus elevated), carcinoembrionic anti-
gen (CEA) (normal versus elevated) and the intention of the applied treatment (palliative ver-
sus neoadjuvant). An overview of the clinicopathological data is given in Table 1.
Local treatment modalities included resection of metastases, radiofrequent ablation, stereo-
tactic radiotherapy, trans-arterial chemoembolization and radio-embolisation procedures.
Discontinuation of a drug in case of combination therapy was not considered as start of a dif-
ferent treatment regimen. Restart of a treatment regimen without interim objective progressive
disease (PD) was considered as treatment continuation. Restart of a treatment regimen after a
treatment free interval with interim objective PD was considered as a new regimen. An over-
view of the treatment schedules of the patients included in the training and validation cohorts
is given in Table 2.
Outcome parameters
Treatment response was evaluated by two radiologists (FSWvdW and JHTMvW) and catego-
rized as complete response (CR), partial response (PR), stable disease (SD) and progressive dis-
ease (PD) according to the Response Evaluation Criteria In Solid Tumors (RECIST version
1.1) [27]. When imaging results were difficult to interpret, independent re-evaluation was per-
formed. PFS was defined as time between start of first line treatment until disease progression
on imaging. When documentation of progression on follow up imaging was not available, a
rise in CEA level was used instead to evaluate PFS. If progression was not observed during
treatment, the date of last imaging was used as follow-up date for the survival analyses. Overall
survival (OS) was defined as time between start of first line treatment until death from any
cause. Survival dates were collected from the local authorities (Gemeentelijke Basis Adminis-
tratie, GBA). Follow up ended on March 1st 2015. An overview of outcome parameters of the
patients included in the training and validation cohorts is given in Table 2.
RNA isolation
Of all 169 tumor tissues 4 μm sections were made, stained with hematoxylin and eosin (H&E)
and evaluated by a GI pathologist (NCTvG or GAM) for tumor cell content. Of the 88 fresh
frozen tumor tissues, areas with the highest tumor cell density were selected and the remaining
tissue was macrodissected and removed from the tissue specimen as previously described [17].
Total RNA was isolated using TRIzol (Invitrogen, Carlsbad, CA, USA) following the manufac-
turer’s guidelines with some modifications [17]. Of the 81 FFPE samples, areas with the highest
tumor cell density were macrodissected from 20-μm sections. RNA was isolated using the
RecoverAll Total Nucleic Acid Isolation Kit (Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s guidelines. RNA quantity of the 169 samples was determined
with a Nanodrop 2000 (Thermo Scientific, MA, USA).
Next generation sequencing and data processing
Next generation sequencing (NGS) using Illumina’s TruSeq Small RNA Sample Preparation
protocol and data filtering were performed as previously described [17]. Illumina’s TruSeq
Small RNA Sample Preparation protocol was used for the generation of cDNA libraries. These
libraries were amplified on the flow cells with Illumina’s cluster station (Illumina Inc, San
Diego, CA, USA) and sequenced using Illumina’s HiSeq 2000 (Illumina Inc, San Diego, CA,
USA). Obtained sequence reads were first quality trimmed, resulting in a>99.9% probability
of a correctly identified base of the remaining nucleotides. Secondly, the reads were clipped for
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adaptor sequences. Thirdly, reads with identical sequences were compiled and counted, result-
ing in only unique sequences. Finally, each unique sequence was mapped to the reference
genome (browser hg19) and only those alignments of at least 18 nucleotides and a maximum
of 2 mismatches were retained.
After data filtering steps, the deep sequencing reads were quantified by mapping them
against the known precursor sequences from mirbase v.19 and the novel candidate precursor
Table 2. Treatment characteristics and response evaluation of the patients in the training and validation cohorts.
Training cohort (N = 88) Validation cohort (N = 81) P value1
First line treatment—N (%) 0.65
Neoadjuvant 12 (13.6) 9 (11.1)
Palliative 76 (86.4) 72 (88.9)
First line treatment scheme—N (%) 0.23
5-FU monotherapy 23 (26.1) 14 (17.3)
Oxaliplatin-based regimens 51 (58.0) 57 (70.4)
Irinotecan-based regimens 14 (15.9) 10 (12.3)
Use of first line Bevacizumab—N (%) 0.35
No 49 (55.7) 51 (63.0)
Yes 39 (44.3) 30 (37.0)
Use of first line Cetuximab or Panitumumab -N (%) 0.72
No 83 (94.3) 78 (96.3)
Yes 5 (5.7) 3 (3.7)
Number of systemic treatment regimens—N (%) 0.74
1 88 (100.0) 81 (100.0)
2 54 (61.4) 55 (67.9)
3 30 (34.1) 33 (40.7)
4 10 (11.4) 13 (16.0)
Local treatment for advanced disease after baseline—N (%) 0.68
No 72 (81.8) 69 (85.2)
Yes 16 (18.2) 12 (14.8)
Best response to first line treatment—N (%) 0.45
Complete response (CR) 0 2 (2.5)
Partial response (PR) 43 (48.9) 36 (44.4)
Stable disease (SD) 27 (30.7) 28 (34.6)
Progressive disease (PD) 18 (20.5) 15 (18.5)
PFS of first line treatment–months (median, range) 0.46
Overall 7.8 (1.3–79.6) 7.4 (1.0–25.1)
CR + PR 10.2 (4.1–79.6) 9.1 (3.5–25.1)
SD 6.6 (2.9–25.6) 7.1(2.4–21.7)
PD 2.0 (1.3–3.0) 2.1 (1.0–5.4)
Survival—months (median, range) 0.16
Overall 21.0 (1.7–79.6) 16.4 (3.5–114.3)
CR + PR 27.4 (8.5–79.6) 21.0 (3.5–75.5)
SD 16.9 (2.9–58.2) 15.1 (3.7–114.3)
PD 7.2 (1.7–41.0) 6.6 (4.1–36.6)
1 P values were calculated with Fisher’s exact test, except for treatment scheme and best response which were calculated with the chi-square test and survival which was
calculated with the log rank test
Abbreviations: PFS, progression free survival
https://doi.org/10.1371/journal.pone.0201809.t002
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sequences resulting from our previous work [17]. Reads that map equally well to the positions
of multiple mature miRs were added to the read counts of those mature miRs. Read counts of
identical mature miRs mapping to related precursors (e.g. hsa-mir-7-1, hsa-mir-7-2, hsa-mir-
7-3) were averaged. Genome data has been deposited at the European Genome-phenome
Archive (EGA, http://www.ebi.ac.uk/ega/) which is hosted at the European Bioinformatics
Institute (EBI), under accession number EGAS00001001127.
Reverse transcription quantitative PCR
Reverse transcription quantitative (RT-q) PCR for miRs was performed using the miRCURY
LNA™ Universal RT microRNA PCR system (Exiqon A/S, Vedbaek, Denmark) according to
the manufacturer’s instructions. The synthetic spike-in UniSp6 was replaced with nuclease
free water (Promega, WI, USA). Complement cDNA was diluted 1:40. RT-qPCR was per-
formed in duplicate according to the manufacturer’s instructions and run on a CFX96
RT-PCR detection system (Bio Rad, CA, USA). For individual miR assays Exiqon LNA primer
sets were used (Exiqon A/S, Vedbaek, Denmark). Average Cq values were normalized to miR-
16-5p as reference miR [28, 29]. RT-qPCRs were repeated with 15 ng input RNA if the stan-
dard deviation of the duplicate was above 0.6 or when no expression was observed. Colorectal
adenocarcinoma cell line HT29 was used as positive control for the assays with miR-16-5p,
miR-17-5p, miR-20a-5p, miR-92a-3p and miR-98-5p. For miR-30a-5p the head and neck
squamous cell carcinoma cell line SCC120 and for miR-92b-3p colorectal adenocarcinoma cell
line H630 were used as positive control. A melt curve analysis was performed for amplification
specificity of each individual target per sample.
Statistical analysis
Read counts of the samples of the training set were normalized using edgeRs TMM method
[30]. Class prediction and differential expression analyses were performed for miRs expressed
in at least 5 samples. Analyses were performed for all identified miRs as well as for the previ-
ously identified subgroup of 222 tumor specific miRs [17].
Treatment response. Predictive covariates for treatment response included age of the
patient, primary tumor differentiation, prior use of adjuvant therapy and the type of systemic
treatment regimen. Global test statistics corrected for these covariates were used to test
whether miR expression levels were associated with response to treatment [31].
Class prediction and miR selection were performed using the GRridge package (version
1.5) in the statistical programming language R [32]. Weighted logistic ridge regression and
posterior forward selection were performed to select the miRs predictive of treatment response
[32]. The total read count and standard deviation of each miR were used as co-data to provide
unbiased weights for prediction and miR selection [32], which lead to a preference for higher
expression levels. Tumor samples of the training set were divided into patients with clinical
benefit (CR, PR or SD) versus patients with PD. Differential expression analyses between the
patients with clinical benefit and those with PD were performed by testing the additive value
of a miR with respect to the aforementioned predictive covariates in a logistics regression set-
ting, followed by a Benjamin-Hochberg correction for multiple testing. FDR values of<0.1
were considered significant.
Survival. Prior to analysis tumor stage at diagnosis (synchronous disease versus metachro-
nous disease), liver metastases only (yes versus no) and intention of the applied treatment (pal-
liative versus neoadjuvant) were added as prognostic covariates for survival analyses. Data on
LDH and CEA levels were missing for 16 and 11 patients respectively and not included as
covariates (Table 1). Differential expression analyses for PFS were performed as described
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above, but with Cox regression instead of logistic regression. FDR values of<0.1 were consid-
ered significant.
Independent validation. To minimize the influence of selection bias on the effect size of
the prediction co-efficients of the selected miRs, the model resulting from the training cohort
was re-estimated in the independent sample set. Model co-efficients and fold changes were
calculated with multivariate logistic regression analysis using Akaike’s information criterion
(AIC)-based backward selection. The training cohort was divided into patients with treatment
response (CR or PR), patients with SD and patients with PD [33]. Data on primary tumor dif-
ferentiation was missing for 12 patients in the validation cohort and missing data was included
as separate level of this covariate. Added predictive value of selected miRs to clinicopathologi-
cal factors was tested using DeLong’s method for comparing the AUCs of paired ROC curves,
as implemented in the R-package ‘pROC’ [34, 35], with a p-value < 0.05 regarded as signifi-
cant added predictive value. Differential expression of the selected predictive miRs was tested
by using the Wilcoxon rank sum test, with a p-value < 0.05 regarded as a significant different
expression level.
Results
Patient and tumor sample characteristics
Of the 88 samples in the training cohort, 81 samples (92%) were chemotherapy naive and 7
samples (8%) were collected after a> 6 months chemotherapy free period. All 81 samples of
the validation cohort were chemotherapy naive. None of the patients in the training cohort
and 10 patients in the validation cohort received neoadjuvant radiotherapy on their primary
rectal tumors, but included tumor biopsies were obtained before start of radiotherapy. Patients
in the training cohort were significantly older than patients in validation cohort (median 65
years versus 61 years respectively, p = 0.01), had a significantly different tumor distribution
throughout the colon with less rectal tumors (10.2% versus 24.7% respectively, p = 0.005),
more often had liver metastases only (45.5% versus 29.6% respectively, p = 0.04) and more
often received prior adjuvant chemotherapy (22.7% versus 4.9% respectively, p = 0.001).
Other patient characteristics were not significantly different between the two groups (Table 1).
Patients received fluoropyrimidine-based treatment as first line treatment for mCRC, except
for 1 patient in the training cohort which received fluoropyrimidine containing adjuvant
treatment for localized disease and was treated with irinotecan monotherapy (Table 2). Tumor
cell content of the samples from the validation set ranged between 40% and 80%, with 55/81
(67.9%) of the samples containing 70% or more tumor cells.
MiR expression profiles obtained by next generation sequencing
The number of nucleotide sequences (reads) obtained by NGS of the 88 fresh-frozen tumor
samples ranged from 6.114.932 to 74.313.067 reads per sample, with a median of 9.179.594
reads per sample. After data filtering steps 541.909.004 nucleotide sequences of at least 18
nucleotides mapped to the reference genome with a maximum of two mismatches, which
was 61.0% of the initial total number of reads. In these sequences 2567 unique mature miR
sequences were identified, consisting of 457 novel candidate miR sequences and 2110 miR
sequences known according to miRbase version 19. The read counts of these 2567 miRs ranged
from 1 to 80.932.357. Of these miRs, 2113 miRs were expressed in at least 5 of the 88 samples
and were included for further analyses. These miRs included 221 of the previously identified
222 tumor specific miRs [17].
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Six-miR expression profile combined with four clinicopathological factors
is predictive for clinical benefit on first line chemotherapy
After normalization of the read counts, class prediction for clinical benefit compared to PD
was performed with all 2113 miRs and with the 221 tumor specific miRs. Age, primary tumor
differentiation, prior use of adjuvant therapy and the type of systemic treatment regimen were
included as predictive covariates. Using global test statistics, the association between all 2113
miRs with clinical benefit resulted in a non-significant p-value of 0.07. The association of the
221 tumor specific miRs with clinical benefit was much stronger and resulted in a significant
correlation between miR expression and response to treatment (p = 0.008). Therefore, expres-
sion levels of non-tumor specific miRs did not add predictive value for clinical benefit to the
tumor specific miRs. Using penalized logistic regression, six miRs were selected to build the
predictive classifier; miR-17-5p, miR-20a-5p, miR-30a-5p, miR-92a-3p, miR-92b-3p and miR-
98-5p. Combination of the expression patterns of these six miRs together with the four clinico-
pathological covariates resulted in a discriminatory performance between patients with and
without clinical benefit from first line treatment, with an AUC of 0.78 (Fig 1A). Using the pre-
dictive classifier without the selected miRs resulted in a non-predictive AUC of 0.35 (Fig 1A).
Probabilities for clinical benefit for individual patients were calculated and cross-validated
using individual expression levels of the six miRs and individual values for the four clinico-
pathological covariates. The median predicted probability for clinical benefit of the 70 patients
with clinical benefit was 0.90 (IQR 0.77–0.97) (Fig 1B). For the 18 patients with PD the median
predicted probability for clinical benefit was 0.60 (IQR 0.47–0.84) (Fig 1B). Two patients
with actual clinical benefit had a low predicted probability for clinical benefit (0.47 and 0.10
respectively). Both patients had SD as best response to first line treatment. The correlation
between the predicted probabilities for clinical benefit with PFS and OS are shown in Fig 1C
and 1D. The correlation with PFS is moderate (spearman’s rho = 0.30), although significant
(p = 0.006). The correlation with OS (spearman’s rho = 0.19) is not significant (p = 0.08). A
low predicted probability for clinical benefit has a high negative predictive value for worse
prognosis (PFS as well as OS), while a high predicted probability for clinical benefit has a low
positive predictive value for a good prognosis (Fig 1C and 1D). To evaluate the individual dis-
criminatory value of the 221 tumor specific miRs, differential expression analyses including
the four predictive covariates were performed between patients with clinical benefit and those
with PD. Seventeen miRs were significantly different expressed (FDR<0.1) between patients
with clinical benefit versus patients with PD during first line treatment (Table 3). Of the six
selected miRs, miR-17-5p, miR-20a-5p and miR-92a-3p were significantly upregulated in the
tumors of the patients with clinical benefit on first line treatment compared to those of the
patients with PD. MiR-30a-5p, miR-92b-3p and miR-98-5p were not significantly different
expressed between the two groups (Table 3).
Prognostic value of the six-miR expression profile
Using global test statistics, the miR expression of all 2113 miRs as well as the 221 tumor specific
miRs were significantly associated with PFS. Again the association of the tumor specific miRs
was stronger (p = 0.02 versus 0.01 respectively). To evaluate the prognostic value of the individ-
ual miRs, a multivariate cox-regression analysis for PFS was performed. Included covariates
were the four predictive covariates used for treatment response analyses, with the addition of
three prognostic covariates; initial tumor stage, liver metastases only and neoadjuvant versus
palliative first line treatment. None of the six miRs were individually significantly associated
with PFS (FDR <0.1), although miR-17-5p, miR-30a-5p and miR-92b-3p showed p-values
smaller than 0.05.
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Fig 1. Performance of the classifier in the training cohort. (A) Receiver operating characteristic (ROC) curve of six-miR classifier predictive for response to first
line systemic treatment for patients with mCRC based on the training cohort (n = 88), resulting in an area under the curve (AUC) of 0.78. Included in the classifier
are miR-17-5p, miR-20a-5p, miR-30a-5p, miR-92a-3p, miR-92b-3p and miR-98-5p and four clinicopathological covariates; prior use of adjuvant therapy, the type of
systemic treatment regimen, age and primary tumor differentiation. When excluding the miRs from the prediction algorithm the AUC drops to 0.35. The false
positive rate (1-specificity) is depicted on the x-axis and, the sensitivity is depicted on the y-axis. (B) Boxplot of the internal cross validated predicted probabilities for
clinical benefit. The median predicted probability for the 70 patients with clinical benefit was 0.90 (IQR: 0.77–0.97). For the 18 patients with progressive disease the
median predicted probability for clinical benefit was 0.60 (IQR: 0.47–0.84). Predicted probabilities were calculated using the expression levels of the six selected miRs
and four clinicopathological covariates. (C) Correlation between the predicted probabilities for clinical benefit (y-axis) with progression free survival (x-axis) of the
training cohort. There is a significant correlation of 0.30 (spearman’s rho) (p = 0.006). (D) Correlation between the predicted probabilities for clinical benefit (y-axis)
with overall survival (x-axis) of the training cohort. There is a correlation of 0.19 (spearman’s rho), which is not significant (p = 0.08).
https://doi.org/10.1371/journal.pone.0201809.g001
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Differential expression analyses for OS were not performed as global test associations of the
miRs with OS were not significant.
Performance of the six-miR expression profile and the four
clinicopathological factors in the independent validation set
The performance of the predictive classifier including the expression levels of miR-17-5p,
miR-20a-5p, miR-30a-5p, miR-92a-3p, miR-92b-3p and miR-98-5p and the four clinicopatho-
logical covariates was evaluated in an independent validation cohort of 81 tumor samples. The
classifier was re-estimated by dividing the patients of the validation cohort into patients with
treatment response (CR or PR), patients with SD and patients with PD. Three comparisons
were made; 1) patients with response versus patients with PD, 2) patients with SD versus
patients with PD and 3) patients with response versus patients with SD.
When re-estimating the model on the patients with treatment response versus the patients
with PD, treatment response was predicted with an AUC of 0.90 with the classifier including
miR-92a and miR-92b (Fig 2A). When excluding these miRs from the model, the AUC
dropped to 0.85 (Fig 2A), this difference was not significant (p = 0.12) indicating that expres-
sion levels of the six selected miRs added no predictive value to clinicopathological factors
alone for this comparison. A negative predictive value (NPV) of 0.9 for predicting PD resulted
in a positive predictive value (PPV) of 0.69 for predicting CR or PR. The prediction model was
not able to separate the patients with SD from those with PD (AUC without miRs = 0.69, with
miRs = 0.72, p = 0.37, Fig 2B) The re-estimated prediction model for separating patients with
Table 3. Differential expression analysis of 20 miRs in the training cohort. The multivariate logistic regression
analysis is based on the tumor specific miRs (N = 221). For each miR, p-values and FDR values of the multivariate
logistic regression analysis and total number of reads are shown. Seventeen miRs were significantly differently
expressed between patients with clinical benefit versus progressive disease on first line systemic treatment. Three of the
6 miRs included in the prediction model were not significantly differently expressed but are included as well. The 6
miRs of the prediction model are shown in bold.
MiR p-value FDR Read count
hsa-miR-592 0.000 0.024 34304
hsa-miR-92a-1-5p 0.000 0.036 7030
hsa-miR-20a-5p 0.000 0.036 495181
hsa-miR-92a-3p 0.001 0.072 11259402
hsa-miR-548ar-5p 0.002 0.072 420
hsa-miR-17-5p 0.002 0.072 347413
hsa-miR-2467-5p 0.002 0.072 2908
hsa-miR-29c-5p 0.003 0.078 3808
hsa-miR-3200-3p 0.003 0.078 2950
hsa-miR-29b-2-5p 0.004 0.081 752
hsa-miR-548h-5p 0.004 0.086 590
hsa-miR-3912-3p 0.005 0.086 1230
hsa-chr16_35996-5p 0.006 0.094 55
hsa-miR-548aj-5p 0.007 0.094 513
hsa-miR-4745-5p 0.007 0.094 78
hsa-miR-548x-5p 0.007 0.094 507
hsa-miR-548g-5p 0.007 0.094 508
hsa-miR-92b-3p 0.010 0.113 652188
hsa-miR-98-5p 0.011 0.118 713894
hsa-miR-30a-5p 0.059 0.332 1010198
https://doi.org/10.1371/journal.pone.0201809.t003
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Fig 2. Performance of the classifier in the validation cohort. (A) ROC curve of the predictive classifier in the
validation cohort for patients with PR or CR on first line systemic treatment (n = 38) compared to patients with PD
(n = 15). Included in the classifier are miR-92a-3p, miR-92b-3p and four clinicopathological covariates. On the x-axis
the false positive rate (1-specificity) is depicted, on the y-axis the sensitivity is depicted. The AUC of the model for
predicting treatment response without miRs is 0.85, compared to 0.90 when including miR-92a-3p and miR-92b-3p to
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treatment response from those with SD included miR-17-5p, miR-92a-3p, miR-92b-3p and
miR-98-5p. Adding those miRs to clinicopathological factors increased the AUC for predicting
treatment response significantly from 0.79 to 0.90 (p = 0.02) (Fig 2C). A NPV of 0.9 for pre-
dicting SD, resulted in a PPV of 0.78 for predicting treatment response.
Normalized expression levels of the six miRs tested in the validation cohort are shown
in Fig 3. MiR-17-5p was significantly higher expressed in patients with treatment response
compared to patients with SD (p = 0.004), but not with PD (p = 0.108). Also miR-20a-5p and
miR-92a-3p were significantly higher expressed in patients with treatment response compared
to patients with SD (p = 0.006 and p = 0.005, respectively), but not with PD (p = 0.790 and
p = 0.179, respectively) (Fig 3). In concordance with the training cohort, miR-30a-5p, mir-
92b-3p and miR-98-5p were not significantly differentially expressed between the three groups
in the validation cohort.
Discussion
CRC is a biologically heterogeneous disease due to the accumulation of genetic and epigenetic
alterations over time. It has been established that CRCs with an identical genetic make-up will
behave in a similar way [36–38]. In this study, we found that tumors of patients with mCRC
may be separated into biological subgroups with a different response to fluoropyrimidine con-
taining first line systemic treatment based on miR expression levels and four clinicopathological
variables. When the expression levels of six miRs (miR-17-5p, miR-20a-5p, miR-30a-5p, miR-
92a-3p, miR-92b-3p and miR-98-5p) are added to the clinicopathological variables (age and pri-
mary tumor differentiation, prior use of adjuvant therapy and the type of systemic treatment
regimen), the AUC for identifying patients with clinical benefit increased from 0.35 to 0.78 in
the training cohort. However, we were not able to validate the added predictive value of these
miRs for all three response groups (treatment response versus SD versus PD) when re-estimat-
ing their predictive value in an independent validation cohort. This may be partially explained
by the difference in predictive power of the four clinicopathological factors between the training
cohort and the validation cohort. Clinicopathological factors did not have predictive power in
the training cohort, while in the validation cohort patient could already be classified based on
clinicopathological factors alone. In the validation cohort, the AUC for separating patients with
treatment response from patients with SD increased significantly when adding the expression
of miR-17-5p, miR-92a-3p, miR-92b-3p and miR-98-5p to the four clinicopathological factors.
MiR-20a-5p and miR-30a-5p did not add predictive value to the other four miRs. This is in
line with previous findings [24, 39], as not all miRs identified in a training cohort will add pre-
dictive value when re-estimating their predictive value in an independent validation cohort.
The increase in AUC for predicting treatment response versus PD and for predicting SD versus
PD was not significant in the validation cohort, which may be partially explained by the relative
high predictive power of the clinicopathological factors alone for separating patients with
the model, this difference is not significant (p = 0.12). (B) ROC curve of the predictive classifier in the validation
cohort for patients with SD on first line systemic treatment (n = 28) compared to patients with PD (n = 15). Included
in the classifier are miR-30a-5p and therapy regimen. On the x-axis the false positive rate (1-specificity) is depicted, on
the y-axis the sensitivity is depicted. The AUC of the model for predicting SD without miRs is 0.69, compared to 0.72
when including miR-30a-5p to the model, this difference is not significant (p = 0.37). (C) ROC curve of the predictive
classifier in the validation cohort for patients with PR or CR on first line systemic treatment (n = 38) compared to
patients with SD (n = 28). Included in the classifier are miR-17-5p, miR-92a-3p, miR-92b-3p and miR-98-5p and
differentiation grade of the primary tumor. On the x-axis the false positive rate (1-specificity) is depicted, on the y-axis
the sensitivity is depicted. The AUC of the model for predicting treatment response without miRs is 0.79, which
increased significantly to 0.90 when including miR-17-5p, miR-92a-3p, miR-92b-3p and miR-98-5p to the model
(p = 0.02).
https://doi.org/10.1371/journal.pone.0201809.g002
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Fig 3. Box-plots of the expression levels of selected miRs in the validation cohort. Expression levels of (A) miR-17-5p, (B) miR-20a-5p, (C)
miR-30a-5p, (D) miR-92a-3p, (E) miR-92b-3p and (F) miR-98-5p for patients with PR or CR, those with SD and those with PD. Median delta Cq
values were normalized to miR-16-5p. MiR-17-5p is significantly higher expressed in patients with response compared to patients with SD
(p = 0.004), but not with PD (p = 0.108). Also miR-20a-5p and miR-92a-3p are significantly higher expressed in patients with response compared
to patients with SD (p = 0.006 and p = 0.005), but not with PD (p = 0.790 and p = 0.179). MiR-30a-5p, miR-92b-3p and miR-98-5p were not
significantly differently expressed between the three groups.
https://doi.org/10.1371/journal.pone.0201809.g003
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treatment response from those with PD (AUC = 0.85). Although the addition of miR expression
levels resulted in an AUC of 0.90 for this comparison, this improvement was not statistically sig-
nificant. Clinicopathological factors alone yielded less predictive value for separating patients
with treatment response from those with SD (AUC = 0.79). However, these patients could be
separated with a significantly higher predictive power when adding miR expression levels
(AUC = 0.90). In the validation cohort patients with SD could not be separated from patients
with PD and the addition of miR expression levels yielded no additional predictive power for
this comparison (AUC = 0.69 and AUC = 0.72 respectively). The different predictive behaviour
of the clinicopathological factors between the training and the validation cohort and between
the different response groups of the validation cohort might possibly be explained by a signifi-
cantly different age distribution, a significant difference in uptake of prior adjuvant therapy,
a difference in metastatic tumor load or a different distribution of rectal and colon tumors
between the two cohorts, however this has to be further explored.
In the training cohort, miR expression profiles were compared between patients with clini-
cal benefit (defined as CR, PR or SD) and patients with PD. As SD is an intermediate pheno-
type between patients who respond to the treatment and patients who progress it might be
more difficult to classify SD using molecular markers [33]. Therefore, in the validation cohort
patients were divided into three different response groups (treatment response versus SD ver-
sus PD)., In this study, miR expression levels of patients with SD resembled those of patients
with PD in the validation cohort, which was in contrast with the training cohort where patients
with SD were separated from those with PD. This indeed indicates the difficulty of classifying
an intermediate phenotype based on molecular markers. The discrepancy might be explained
by several factors. Firstly, the distribution of rectal, left sided and right sided CRCs differed
between the training and the validation cohort, with more rectal tumors in the validation
cohort and it is well known that the genetic make-up of rectal tumors differs from right-sided
and left-sided CRCs [36,40]. Secondly, the metastatic tumor load of the patients in the training
cohort was less than in the validation cohort with more often liver metastases only (45.5% ver-
sus 29.6% respectively). Thirdly, patients in the training cohort more often received prior adju-
vant chemotherapy than patients in the validation cohort (22.7% versus 4.9% respectively),
which might have induced alterations in miR expression. Fourthly, to resemble clinical prac-
tice during the validation process, no minimal tumor cell percentage was required for inclu-
sion in the validation cohort. This could have led to a relatively higher abundance of miRs
expressed in stromal tissue in the validation cohort, contributing to a different genetic make-
up of both SD groups. The difference in miR expression levels of patients with SD between the
validation and the training cohorts could not be explained by a different prognosis since PFS
of patients with SD was similar (6.6 months versus 7.1 months respectively). Also, it is unlikely
that intra-tumor heterogeneity of miR expression and sampling bias played a role, as the miRs
selected in this study were not significantly differentially expressed between multiple tumor
locations within the same patient [17].
Up-regulated as well as down-regulated miRs play a role in the carcinogenesis of CRC [41–
43]. Up-regulation of mature miRs may occur due to transcriptional activation or amplifica-
tion of miR encoding genes, whereas down-regulation may result from deletion of a particular
chromosomal region, epigenetic silencing, or defects in miR biogenesis. Previous studies relat-
ing miR expression to treatment response in mCRC used PCR or micro-array based platforms
to identify predictive miRs in their training cohorts [18, 19, 21, 22]. Consequently, these stud-
ies were limited to the analysis of a maximum of 1367 miRs. Previous studies analysing the
miR transcriptome by NGS did not correlate the obtained miR expression profiles to treatment
response in mCRC [44–46]. In the current study, 2567 miRs were analysed using NGS in
an unbiased manner and correlated with treatment response. The selection of miRs in the
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training cohort was based on their predictive performance as well as on their relative abun-
dance in CRC tissue, which may enhance future biomarker development as miRs with a rela-
tive robust expression level will be more easy to quantify using RT-qPCR based platforms.
Development of miR based biomarkers to predict treatment response in the palliative as well
as in the neoadjuvant setting is of clinical relevance, as such biomarkers are currently largely
lacking [9, 47]. The prediction of non-response (PD or SD) is especially important in the
neoadjuvant setting as prediction of non-response will prevent treatment of patients in which
systemic therapy does not result in increased resection rates for advanced disease. In this study
a NPV of 0.9 for predicting non-response could be reached at a PPV of 0.69–0.78 for predict-
ing treatment response. Therefore, the miRs identified in this study might serve as potential
candidate biomarkers for predicting response to neoadjuvant treatment, which has to be fur-
ther explored in studies evaluating the clinical relevance of miR based biomarkers. The poten-
tial of miR based biomarkers was demonstrated in the validation cohort using RT-qPCR on
FFPE tissue without the need for a minimal tumor cell percentage. FFPE tissue specimens are
readily available in clinical practice and miR expression levels are highly stable detectable in
these FFPE tissue specimens [14]. In this study, patients were treated with different fluoropyri-
midine containing treatment regimens. Therefore, miRs that predict response to an individual
drug might have been missed [48, 49]. However, by excluding patients who underwent radio-
therapy or systemic treatment less than six months before tissue sampling, effects of these
treatments on miR expression profiles were minimized [50,51].
Previously, we demonstrated tumor specificity of the selected miRs for mCRC tissue com-
pared to non-tumorous colorectal tissue, with miR-17-5p, miR-20a-5p, miR-92a-3p, miR-92b-
3p and miR-98-5p being significantly upregulated and miR-30a-5p being significantly downre-
gulated in mCRC tissue compared to non-tumorous tissue [17]. The results of this study indi-
cated that miR-17-5p, miR-20a-5p and miR-92a-3p were also significantly upregulated in
patients with response on first line treatment. Interestingly, those three miRs belong to the miR-
17-92 cluster, which contains 6 oncogenic miRs collectively named as “OncomiR-1” [52]. Upre-
gulation of this cluster was associated with adenoma to carcinoma progression [53]. Recently, a
higher expression of this cluster was observed in chemosensitive compared to chemoresistant
pancreatic cancer stem cells [54]. Pancreatic stem cells lost their stem-like features when the
miR-17-92 cluster was overexpressed resulting in reduced self-renewal capacity and increased
proliferation rate as well as chemosensitivity [54]. Our finding that overexpression of the miR-
17-92 cluster may also result in chemosensitivity of mCRC is in concordance with previous
reports on localized CRC, which indicated that a higher expression of miR-20a-5p was associ-
ated with a favorable response to adjuvant fluorouracil based chemotherapy [24]. However,
results are not unambiguously since elevated expression of miR-17 was previously also associ-
ated with resistance to 5-FU, oxaliplatin and irinotecan by repressing PTEN expression [55].
In conclusion, this study analysed the miR transcriptome using an unbiased whole genome
approach and identified a six miR expression signature with potential to improve the predic-
tion of treatment response to fluoropyrimidine containing first line systemic treatment
regimens in patients with mCRC. The identified miRs have potential to serve as candidate bio-
markers for predicting treatment response, when this signature is combined with four clinico-
pathological factors., however their clinical relevance has to be further explored.
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